Pradaxa fall-out

Following a spate of media coverage outlining the dangers of the anticoagulant drug dabigatran (Pradaxa), GPs should expect to see an influx of patients wanting to drop their medication, the RACGP warns.

Last week, an analysis published in The BMJ revealed Pradaxa’s fickle pharmacokinetics can cause a fivefold variation of plasma concentration that may put some patients with atrial fibrillation at risk of serious bleeding, and leave others untreated for stroke